Literature DB >> 26144349

Genetic purgatory and the cardiac channelopathies: Exposing the variants of uncertain/unknown significance issue.

Michael J Ackerman1.   

Abstract

Merriam-Webster's online dictionary defines purgatory as "an intermediate state after death for expiatory purification" or more specifically as "a place or state of punishment wherein according to Roman Catholic doctrine the souls of those who die in God׳s grace may make satisfaction for past sins and so become fit for heaven." Alternatively, it is defined as "a place or state of temporary suffering or misery." Either way, purgatory is a place where you are stuck, and you don't want to be stuck there. It is in this context that the term genetic purgatory is introduced. Genetic purgatory is a place where the genetic test-ordering physician and patients and their families are stuck when a variant of uncertain/unknown significance (VUS) has been elucidated. It is in this dark place where suffering and misery are occurring because of unenlightened handling of a VUS, which includes using the VUS for predictive genetic testing and making radical treatment recommendations based on the presence or absence of a so-called maybe mutation. Before one can escape from this miserable place, one must first recognize that one is stuck there. Hence, the purpose of this review article is to fully expose the VUS issue as it relates to the cardiac channelopathies and make the cardiologists/geneticists/genetic counselors who order such genetic tests believers in genetic purgatory. Only then can one meaningfully attempt to get out of that place and seek to promote a VUS to disease-causative mutation status or demote it to an utterly innocuous and irrelevant variant.
Copyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; channelopathies; genetic purgatory; genetic testing; ion channels; long QT syndrome

Mesh:

Year:  2015        PMID: 26144349     DOI: 10.1016/j.hrthm.2015.07.002

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  52 in total

1.  Genetic variants and disease: correlate or cause?

Authors:  Maiko Matsui; Geoffrey S Pitt
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

2.  Genome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.

Authors:  Priyanka Garg; Angelos Oikonomopoulos; Haodong Chen; Yingxin Li; Chi Keung Lam; Karim Sallam; Marco Perez; Robert L Lux; Michael C Sanguinetti; Joseph C Wu
Journal:  J Am Coll Cardiol       Date:  2018-07-03       Impact factor: 24.094

3.  Long QT syndrome type 5-Lite: Defining the clinical phenotype associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common genetic variant.

Authors:  Conor M Lane; John R Giudicessi; Dan Ye; David J Tester; Ram K Rohatgi; J Martijn Bos; Michael J Ackerman
Journal:  Heart Rhythm       Date:  2018-04-03       Impact factor: 6.343

4.  Variants of Uncertain Significance: Should We Revisit How They Are Evaluated and Disclosed?

Authors:  Ana Morales; Ray E Hershberger
Journal:  Circ Genom Precis Med       Date:  2018-06

5.  The accessibility and utilization of genetic testing for inherited heart rhythm disorders: a Canadian cross-sectional survey study.

Authors:  Thomas M Roston; Laura Dewar; Sonia Franciosi; Julie Hathaway; Kirsten Bartels; Taylor Cunningham; Karen A Gibbs; Sam Sheps; Zachary W M Laksman; Shubhayan Sanatani; Andrew D Krahn
Journal:  J Community Genet       Date:  2017-11-23

6.  Reclassification of Variants of Uncertain Significance in Children with Inherited Arrhythmia Syndromes is Predicted by Clinical Factors.

Authors:  Jeffrey S Bennett; Madison Bernhardt; Kim L McBride; Shalini C Reshmi; Erik Zmuda; Naomi J Kertesz; Vidu Garg; Sara Fitzgerald-Butt; Anna N Kamp
Journal:  Pediatr Cardiol       Date:  2019-09-18       Impact factor: 1.655

7.  RRAD mutation causes electrical and cytoskeletal defects in cardiomyocytes derived from a familial case of Brugada syndrome.

Authors:  Nadjet Belbachir; Vincent Portero; Zeina R Al Sayed; Jean-Baptiste Gourraud; Florian Dilasser; Laurence Jesel; Hongchao Guo; Haodi Wu; Nathalie Gaborit; Christophe Guilluy; Aurore Girardeau; Stephanie Bonnaud; Floriane Simonet; Matilde Karakachoff; Sabine Pattier; Carol Scott; Sophie Burel; Céline Marionneau; Caroline Chariau; Anne Gaignerie; Laurent David; Emmanuelle Genin; Jean-François Deleuze; Christian Dina; Vincent Sauzeau; Gervaise Loirand; Isabelle Baró; Jean-Jacques Schott; Vincent Probst; Joseph C Wu; Richard Redon; Flavien Charpentier; Solena Le Scouarnec
Journal:  Eur Heart J       Date:  2019-10-01       Impact factor: 29.983

Review 8.  Pulmonary fibrosis in the era of stratified medicine.

Authors:  Susan K Mathai; Chad A Newton; David A Schwartz; Christine Kim Garcia
Journal:  Thorax       Date:  2016-10-31       Impact factor: 9.139

9.  Minding the Genes: a Multidisciplinary Approach towards Genetic Assessment of Cardiovascular Disease.

Authors:  Ashley Rhodes; Lindsey Rosman; John Cahill; Jodie Ingles; Brittney Murray; Crystal Tichnell; Cynthia A James; Samuel F Sears
Journal:  J Genet Couns       Date:  2016-09-30       Impact factor: 2.537

10.  Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis.

Authors:  Justin T Marinko; Hui Huang; Wesley D Penn; John A Capra; Jonathan P Schlebach; Charles R Sanders
Journal:  Chem Rev       Date:  2019-01-04       Impact factor: 60.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.